Literature DB >> 11072385

Nicotine self-administration in animals as a dependence model.

W A Corrigall1.   

Abstract

Various animal models of nicotine dependence now exist. To study the positive reinforcing effects of nicotine, there are choices of animal species, strains, and operant paradigms to use. This manuscript describes the use of one particular paradigm, a model in which work is done by laboratory animals to obtain intravenous infusions of nicotine. This model is particularly useful for examining the mechanisms in the brain that are responsible for the maintenance of drug-taking behavior. Two examples of ongoing studies of the mechanisms of dependence are discussed: the role of cholinergic projections to midbrain dopamine cells, and the influence of opioid receptors in the vicinity of these same dopamine cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11072385     DOI: 10.1080/14622299050011121

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  64 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation.

Authors:  Gary E Swan; Karen Suchanek Hudmon; Lisa M Jack; Kymberli Hemberger; Dorit Carmelli; Taline V Khroyan; Huijun Z Ring; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Dale McBride; Neal Benowitz; Chris Webster; Kirk C Wilhelmsen; Heidi S Feiler; Barbara Koenig; Lorraine Caron; Judy Illes; Li S-C Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

3.  Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats.

Authors:  Xia Li; Manoranjan S D'Souza; Ana M Niño; James Doherty; Alan Cross; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2016-02-13       Impact factor: 4.530

4.  Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.

Authors:  Mark G LeSage; Daniel E Keyler; Yoko Hieda; Greg Collins; Danielle Burroughs; Chap Le; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2005-07-01       Impact factor: 4.530

Review 5.  Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.

Authors:  Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 6.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

7.  A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats.

Authors:  Andrew C Harris; Paul R Pentel; Danielle Burroughs; Mylissa D Staley; Mark G Lesage
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

8.  Nicotine psychopharmacology research: advancing science, public health, and global policy.

Authors:  Jack E Henningfield; Ian P Stolerman; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2006-03       Impact factor: 4.530

9.  How Intravenous Nicotine Administration in Smokers Can Inform Tobacco Regulatory Science.

Authors:  Kevin P Jensen; Elise E DeVito; Mehmet Sofuoglu
Journal:  Tob Regul Sci       Date:  2016-10-01

10.  The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use.

Authors:  Sarah S Dermody; Jennifer W Tidey; Rachel L Denlinger; Lauren R Pacek; Mustafa al'Absi; David J Drobes; Dorothy K Hatsukami; Ryan Vandrey; Eric C Donny
Journal:  Alcohol Clin Exp Res       Date:  2016-02-25       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.